

Product and Ordering Information

NDC No.

70842-240-01

How supplied

REZZAYO® (rezafungin for injection) is supplied as sterile white to pale yellow solid (cake or powder) in a single-dose 20 mL Type I glass vial with a stopper, an aluminum seal, and blue polypropylene flip-off cap. The vial stopper is not made with natural rubber latex.

Packaging configuration

One single-dose vial of REZZAYO® 200 mg (NDC 70842-240-01).

Storage

REZZAYO® vials should be stored at 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) permitted.

How to order

REZZAYO® is available through the following distributors.



Practice Type	Distributor	Phone	Web	Order Number
Hospitals	Cardinal Specialty Pharmaceutical Distribution (CAH SPD)	855-855-0708	pdlogin.cardinalhealth.com	5857990
	ASD Healthcare (ABSG)	800-746-6273	www.asdhealthcare.com	10281238
	McKesson Plasma and Biologics	877-625-2566	connect.mckesson.com	3034790
Clinics Infusion centers Physician offices Home infusion	Metro Medical (Cardinal Health)	800-768-2002	www.metromedicalorder.com	202401
	Besse Medical	800-543-2111	www.besse.com	10281194
	McKesson Plasma and Biologics	877-625-2566	connect.mckesson.com	3034790
	McKesson Specialty Health	800-482-6700	mscs.mckesson.com	5020202
Oncology practices	Cardinal SPD	877-453-3972	pdlogin.cardinalhealth.com	5857990
	Oncology Supply	800-633-7555	www.oncologysupply.com	10281196
	McKesson Specialty Health	800-482-6700	mscs.mckesson.com	5020202

**Please see Important Safety Information on reverse and
accompanying full [Prescribing Information](#).**

REZZAYO® (rezafungin for injection)

MEDICAL INFORMATION

For medical inquiries or to report an adverse event, other safety-related information, or product complaints, please contact Medical Information.



1-844-MED-MLNT
(1-844-633-6568)



medinfo@melinta.com



melintamedicalinformation.com

* INDICATIONS AND USAGE

REZZAYO® is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.

Limitations of Use

REZZAYO® has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to *Candida*.

IMPORTANT SAFETY INFORMATION

Contraindications

REZZAYO® is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

Warnings and Precautions

- Hypersensitivity Reactions, including Anaphylaxis:** Cases of serious hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving REZZAYO®. If these reactions occur, discontinue REZZAYO® and administer appropriate treatment.
- Infusion-related Reactions:** REZZAYO® may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion.
- Photosensitivity:** REZZAYO® may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation.
- Hepatic Adverse Reactions:** Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO®. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO® therapy.

Adverse Reactions

Most common adverse reactions (incidence $\geq 5\%$) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia.

Please see accompanying full [Prescribing Information](#).



CorMedix Therapeutics

REZZAYO® is a registered trademark of Melinta Therapeutics, LLC,
generally known as CorMedix Therapeutics.
© 2025 Melinta Therapeutics, LLC. All rights reserved. 12/2025 PP-REZ-US-0223 (V4.0)

Once-weekly
REZZAYO™
(rezafungin for injection)